NCT02370524 - Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Alzheimer's Disease (AD)

Interventions

DRUG

[18F]T807

All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven